Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 9/20 | 0.61 |
| ▸ | PARP15 | Q460N3 | 4/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.61 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.61 |
| ▸ | PARP11 | Q9NR21 | 1/20 | 0.61 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | RAB9A | P51151 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 1/20 | 0.48 |
| ▸ | PLAU | P00749 | 1/20 | 0.48 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.48 |
| ▸ | MMP13 | P45452 | 1/20 | 0.47 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL815029 | 0.82 | TSHR (0.50) | HPGDALDH1A1MAPTTSHRHTT | |
| SCHEMBL3238552 | 0.79 | CES2 (0.70) | PARP10HPGDKMT2APARP4MAPT | |
| SCHEMBL25046383 | 0.79 | ELANE (0.42) | PARP10PARP15HPGDALDH1A1KMT2A | |
| Terephthalic Acid SCHEMBL9861713 | 0.78 | PARP10 (0.78) | PARP10PARP15HPGDALDH1A1KMT2A | |
| SCHEMBL22281 | 0.78 | PARP10 (0.78) | PARP10PARP15HPGDALDH1A1KMT2A | |
| SCHEMBL5581520 | 0.78 | PARP10 (0.78) | PARP10PARP15HPGDALDH1A1KMT2A | |
| SCHEMBL766069 | 0.78 | PARP10 (0.78) | PARP10PARP15HPGDALDH1A1KMT2A | |
| SCHEMBL26728639 | 0.78 | ADORA3 (0.50) | PARP10PARP15HPGDALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL9633355 | 0.76 | PARP10 (0.75) | PARP10PARP15HPGDALDH1A1KMT2A | |
| Ammonia Solution, Strong SCHEMBL9436485 | 0.76 | PARP10 (0.75) | PARP10PARP15HPGDALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017218714-A1 | GENETICALLY MODIFIED CELLS, TISSUES, AND ORGANS FOR TREATING DISEASE | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-12-21 | — | — | WO | disclosed |
| US-20080146768-A1 | PROCESSES FOR PREPARING POLYMERS USING ALPHA,OMEGA-DIFUNCTIONAL ALDARAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY | 2008-06-19 | — | — | US | disclosed |
| EP-1858955-A1 | PROCESSES USING ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES AS MONOMERS AND CROSSLINKERS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20060264672-A1 | Processes using alpha, omega-difunctional aldaramides as monomers and crosslinkers | E. I. DU PONT DE NEMOURS AND COMPANY | 2006-11-23 | — | — | US | disclosed |
| WO-2006091901-A1 | PROCESSES USING ALPHA, OMEGA-DIFUNCTIONAL ALDARAMIDES AS MONOMERS AND CROSSLINKERS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2006-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264672-A1 | Processes using alpha, omega-difunctional aldaramides as monomers and crosslinkers | ALOX5, GSTO1, FASN | PARP10 1884/4885PARP15 1250/4885HPGD 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.